Catalyst Wire Dossier Catalyst Wire Dossier

E2027 (Hereinafter Referred to as Irsenontrine)

Irsenontrine · Eisai Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for E2027 (Hereinafter Referred to as Irsenontrine), covering 2022-08-01 to 2022-08-01. Get the full timeline:

Most recent: Clinical Trial Update: Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies [Phase 2]

See pricing